Activity of ixabepilone in oestrogen receptor-negative and oestrogen receptor-progesterone receptor-human epidermal growth factor receptor 2-negative metastatic breast cancer

Xavier B. Pivot; Rubi K. Li; Eva S. Thomas; Hyun Cheol Chung; Luis E. Fein; Valorie F. Chan; Jacek Jassem; Fernando Hurtado de Mendoza; Pralay Mukhopadyay; Henri H. Roché

doi:10.1016/j.ejca.2009.07.015

Activity of ixabepilone in oestrogen receptor-negative and oestrogen receptor-progesterone receptor-human epidermal growth factor receptor 2-negative metastatic breast cancer

Xavier B. Pivot, Rubi K. Li, Eva S. Thomas, Hyun Cheol Chung, Luis E. Fein, Valorie F. Chan, Jacek Jassem, Fernando Hurtado de Mendoza, Pralay Mukhopadyay, Henri H. Roché

Department of Internal Medicine

Research output: Contribution to journal › Article › peer-review

21 Citations (Scopus)

Abstract

Oestrogen receptor (ER)-negative breast cancer, including oestrogen receptor-, progesterone receptor- and human epidermal growth factor receptor 2-negative (ER/PR/HER2-negative) breast cancer, is more aggressive than ER-positive disease. A major limitation in the treatment of ER-negative disease subtypes is the inherent insensitivity to hormonal agents (tamoxifen, aromatase inhibitors) that are widely used in the treatment of breast cancer. Thus, therapeutic options for poor prognosis patients with ER-negative breast cancer are limited to a handful of chemotherapeutic agents, and new agents are needed to improve the treatment of this disease. Ixabepilone, a novel epothilone B analogue with low susceptibility to cellular mechanisms that confer resistance to taxanes and other chemotherapeutic agents, has demonstrated potent preclinical antitumour activity in multiple models, including those with primary or acquired drug resistance. This review summarises the results of a prospective subset analysis from a phase III clinical trial evaluating ixabepilone for the treatment of metastatic breast cancer (MBC), in which efficacy and safety were evaluated in patients with ER-negative and ER/PR/HER2-negative disease.

Original language	English
Pages (from-to)	2940-2946
Number of pages	7
Journal	European Journal of Cancer
Volume	45
Issue number	17
DOIs	https://doi.org/10.1016/j.ejca.2009.07.015
Publication status	Published - 2009 Nov

Bibliographical note

Funding Information:
The authors take full responsibility for the content of this publication and confirm that it reflects their viewpoint and medical expertise. They also wish to acknowledge IneXel and StemScientific, funded by Bristol-Myers Squibb, for providing writing and editing support. Bristol-Myers Squibb did not influence the content of the manuscript, nor did the authors receive financial compensation for authoring the manuscript.

Funding Information:
Xavier Pivot received a commercial research grant from Roche and speakers bureau honoraria from Roche and GlaxoSmithKline. He also served as a consultant on advisory boards for Bristol-Myers Squibb and Cephalon. Jacek Jassem and Henri Roché served as consultants on advisory boards for Bristol-Myers Squibb. Pralay Mukhopadyay is an employee of Bristol-Myers Squibb Company, Inc.

All Science Journal Classification (ASJC) codes

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.ejca.2009.07.015

Cite this

Pivot, X. B., Li, R. K., Thomas, E. S., Chung, H. C., Fein, L. E., Chan, V. F., Jassem, J., Mendoza, F. H. D., Mukhopadyay, P., & Roché, H. H. (2009). Activity of ixabepilone in oestrogen receptor-negative and oestrogen receptor-progesterone receptor-human epidermal growth factor receptor 2-negative metastatic breast cancer. European Journal of Cancer, 45(17), 2940-2946. https://doi.org/10.1016/j.ejca.2009.07.015

@article{b40805f2d330458ea5a44c08313b0a6e,

title = "Activity of ixabepilone in oestrogen receptor-negative and oestrogen receptor-progesterone receptor-human epidermal growth factor receptor 2-negative metastatic breast cancer",

abstract = "Oestrogen receptor (ER)-negative breast cancer, including oestrogen receptor-, progesterone receptor- and human epidermal growth factor receptor 2-negative (ER/PR/HER2-negative) breast cancer, is more aggressive than ER-positive disease. A major limitation in the treatment of ER-negative disease subtypes is the inherent insensitivity to hormonal agents (tamoxifen, aromatase inhibitors) that are widely used in the treatment of breast cancer. Thus, therapeutic options for poor prognosis patients with ER-negative breast cancer are limited to a handful of chemotherapeutic agents, and new agents are needed to improve the treatment of this disease. Ixabepilone, a novel epothilone B analogue with low susceptibility to cellular mechanisms that confer resistance to taxanes and other chemotherapeutic agents, has demonstrated potent preclinical antitumour activity in multiple models, including those with primary or acquired drug resistance. This review summarises the results of a prospective subset analysis from a phase III clinical trial evaluating ixabepilone for the treatment of metastatic breast cancer (MBC), in which efficacy and safety were evaluated in patients with ER-negative and ER/PR/HER2-negative disease.",

author = "Pivot, {Xavier B.} and Li, {Rubi K.} and Thomas, {Eva S.} and Chung, {Hyun Cheol} and Fein, {Luis E.} and Chan, {Valorie F.} and Jacek Jassem and Mendoza, {Fernando Hurtado de} and Pralay Mukhopadyay and Roch{\'e}, {Henri H.}",

note = "Funding Information: The authors take full responsibility for the content of this publication and confirm that it reflects their viewpoint and medical expertise. They also wish to acknowledge IneXel and StemScientific, funded by Bristol-Myers Squibb, for providing writing and editing support. Bristol-Myers Squibb did not influence the content of the manuscript, nor did the authors receive financial compensation for authoring the manuscript. Funding Information: Xavier Pivot received a commercial research grant from Roche and speakers bureau honoraria from Roche and GlaxoSmithKline. He also served as a consultant on advisory boards for Bristol-Myers Squibb and Cephalon. Jacek Jassem and Henri Roch{\'e} served as consultants on advisory boards for Bristol-Myers Squibb. Pralay Mukhopadyay is an employee of Bristol-Myers Squibb Company, Inc. ",

year = "2009",

month = nov,

doi = "10.1016/j.ejca.2009.07.015",

language = "English",

volume = "45",

pages = "2940--2946",

journal = "European Journal of Cancer",

issn = "0959-8049",

publisher = "Elsevier Limited",

number = "17",

}

Pivot, XB, Li, RK, Thomas, ES, Chung, HC, Fein, LE, Chan, VF, Jassem, J, Mendoza, FHD, Mukhopadyay, P & Roché, HH 2009, 'Activity of ixabepilone in oestrogen receptor-negative and oestrogen receptor-progesterone receptor-human epidermal growth factor receptor 2-negative metastatic breast cancer', European Journal of Cancer, vol. 45, no. 17, pp. 2940-2946. https://doi.org/10.1016/j.ejca.2009.07.015

Activity of ixabepilone in oestrogen receptor-negative and oestrogen receptor-progesterone receptor-human epidermal growth factor receptor 2-negative metastatic breast cancer. / Pivot, Xavier B.; Li, Rubi K.; Thomas, Eva S. et al.
In: European Journal of Cancer, Vol. 45, No. 17, 11.2009, p. 2940-2946.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Activity of ixabepilone in oestrogen receptor-negative and oestrogen receptor-progesterone receptor-human epidermal growth factor receptor 2-negative metastatic breast cancer

AU - Pivot, Xavier B.

AU - Li, Rubi K.

AU - Thomas, Eva S.

AU - Chung, Hyun Cheol

AU - Fein, Luis E.

AU - Chan, Valorie F.

AU - Jassem, Jacek

AU - Mendoza, Fernando Hurtado de

AU - Mukhopadyay, Pralay

AU - Roché, Henri H.

N1 - Funding Information: The authors take full responsibility for the content of this publication and confirm that it reflects their viewpoint and medical expertise. They also wish to acknowledge IneXel and StemScientific, funded by Bristol-Myers Squibb, for providing writing and editing support. Bristol-Myers Squibb did not influence the content of the manuscript, nor did the authors receive financial compensation for authoring the manuscript. Funding Information: Xavier Pivot received a commercial research grant from Roche and speakers bureau honoraria from Roche and GlaxoSmithKline. He also served as a consultant on advisory boards for Bristol-Myers Squibb and Cephalon. Jacek Jassem and Henri Roché served as consultants on advisory boards for Bristol-Myers Squibb. Pralay Mukhopadyay is an employee of Bristol-Myers Squibb Company, Inc.

PY - 2009/11

Y1 - 2009/11

N2 - Oestrogen receptor (ER)-negative breast cancer, including oestrogen receptor-, progesterone receptor- and human epidermal growth factor receptor 2-negative (ER/PR/HER2-negative) breast cancer, is more aggressive than ER-positive disease. A major limitation in the treatment of ER-negative disease subtypes is the inherent insensitivity to hormonal agents (tamoxifen, aromatase inhibitors) that are widely used in the treatment of breast cancer. Thus, therapeutic options for poor prognosis patients with ER-negative breast cancer are limited to a handful of chemotherapeutic agents, and new agents are needed to improve the treatment of this disease. Ixabepilone, a novel epothilone B analogue with low susceptibility to cellular mechanisms that confer resistance to taxanes and other chemotherapeutic agents, has demonstrated potent preclinical antitumour activity in multiple models, including those with primary or acquired drug resistance. This review summarises the results of a prospective subset analysis from a phase III clinical trial evaluating ixabepilone for the treatment of metastatic breast cancer (MBC), in which efficacy and safety were evaluated in patients with ER-negative and ER/PR/HER2-negative disease.

AB - Oestrogen receptor (ER)-negative breast cancer, including oestrogen receptor-, progesterone receptor- and human epidermal growth factor receptor 2-negative (ER/PR/HER2-negative) breast cancer, is more aggressive than ER-positive disease. A major limitation in the treatment of ER-negative disease subtypes is the inherent insensitivity to hormonal agents (tamoxifen, aromatase inhibitors) that are widely used in the treatment of breast cancer. Thus, therapeutic options for poor prognosis patients with ER-negative breast cancer are limited to a handful of chemotherapeutic agents, and new agents are needed to improve the treatment of this disease. Ixabepilone, a novel epothilone B analogue with low susceptibility to cellular mechanisms that confer resistance to taxanes and other chemotherapeutic agents, has demonstrated potent preclinical antitumour activity in multiple models, including those with primary or acquired drug resistance. This review summarises the results of a prospective subset analysis from a phase III clinical trial evaluating ixabepilone for the treatment of metastatic breast cancer (MBC), in which efficacy and safety were evaluated in patients with ER-negative and ER/PR/HER2-negative disease.

UR - http://www.scopus.com/inward/record.url?scp=70449096190&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70449096190&partnerID=8YFLogxK

U2 - 10.1016/j.ejca.2009.07.015

DO - 10.1016/j.ejca.2009.07.015

M3 - Article

C2 - 19683429

AN - SCOPUS:70449096190

SN - 0959-8049

VL - 45

SP - 2940

EP - 2946

JO - European Journal of Cancer

JF - European Journal of Cancer

IS - 17

ER -

Activity of ixabepilone in oestrogen receptor-negative and oestrogen receptor-progesterone receptor-human epidermal growth factor receptor 2-negative metastatic breast cancer

Abstract

Bibliographical note

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this